Advertisement

Classifying patients and monitoring the outcomes of cell based therapies using immunomics

      We have developed a novel approach to categorize immunity in patients that uses a combination of whole blood flow cytometry and hierarchical clustering. Our approach is based on flow cytometry capable of enumerating each of the major leukocyte subsets in unfractionated, whole blood. We have previously demonstrated this approach using 40 healthy volunteers and 120 patients with glioblastoma, renal cell carcinoma, non-Hodgkin lymphoma, ovarian cancer or acute lung injury. After normalization, we used unsupervised hierarchical clustering to sort individuals by similarity into discrete groups we call immune profiles. We identified specific immune profiles with improved survival (p<0.01). What is particularly noteworthy is that these immune profiles identified patients with similar immune status independent of the underlying diagnosis. This analysis also allowed determination of unique relationships between immune markers. For example, two critical myeloid phenotypes (the immunosuppressive CD14+HLA-DRlo/neg monocytes and Lin-CD33+HLA-DR- myeloid derived suppressor cells) independently segregated among patients. We have now developed our third generation immune profiling panel. This panel consists of a 10 color, 8-tube protocol set capable of identifying more than 100 distinct phenotypes. We are using this panel to identify unique immune profiles in patients undergoing cell-based therapy including dendritic cell vaccines and mesenchymal stem cell therapies. To date, we have evaluated approximately 200 patients and healthy volunteers using this approach. We will present data on the power of this approach in cancer and demonstrate its potential to select and monitor patients undergoing cell based therapies.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect